Peptide-based inhibitors of the phagocyte NADPH oxidase

Biochemical Pharmacology

Volumn 80, Issue 6, 2010, Pages 778-785

  El Benna, Jamel ^a,b   Dang, Pham My Chan ^a,b   Périanin, Axel ^a,b,c  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT COCHIN   (France)

Author keywords

Gp91phox NOX2; Inhibitors; NADPH oxidase; P22phox; P47phox; Phagocytes

Indexed keywords

ANTIINFLAMMATORY AGENT; APOCYNIN; ARSENOSOBENZENE; GLYCOPROTEIN GP 91; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN P22; PROTEIN P40; PROTEIN P47; PROTEIN P67; RAC1 PROTEIN; RAC2 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2;

AMINO ACID SEQUENCE; BACTERIAL INFECTION; CHRONIC GRANULOMATOUS DISEASE; DRUG INHIBITION; HOST RESISTANCE; INFLAMMATION; MACROPHAGE; MONOCYTE; MYCOSIS; NEUTROPHIL; NONHUMAN; NOTE; PHAGOCYTE; PRIORITY JOURNAL; RESPIRATORY BURST;

EID: 77954758294     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.05.020     Document Type: Note

References (75)

1. Babior B.M. Oxidants from phagocytes: agents of defense and destruction. Blood 1984, 64:959-966.
2. Hampton M.B., Kettle A.J., Winterbourn C.C. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998, 92:3007-3017.
3. El-Benna J., Dang P.M., Gougerot-Pocidalo M.A., Elbim C. Phagocyte NADPH oxidase: a multicomponent enzyme essential for host defenses. Arch Immunol Ther Exp (Warsz) 2005, 53:199-206.
4. Roos D., De Boer M., Kuribayashi F., Meischl, Weening R.S., Segal A.W., et al. Bernatowska-Matusskiewicz and middleton-Price H: mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Blood 1996, 87:1663-1681.
5. Babior B.M. Phagocytes and oxidative stress. Am J Med 2000, 109:33-44.
6. Lambeth J.D. Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med 2007, 43:332-347.
7. Groemping Y., Rittinger K. Activation and assembly of the NADPH oxidase: a structural perspective. Biochem J 2005, 386:401-416.
8. Babior B.M. NADPH oxidase: an update. Blood 1999, 93:1464-1476.
9. Vignais P.V. The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell Mol Life Sci 2002, 59:1428-1459.
10. Regier D.S., Waite K.A., Wallin R., McPhail L.C. A phosphatidic acid-activated protein kinase and conventional protein kinase C isoforms phosphorylate p22(phox), an NADPH oxidase component. J Biol Chem 1999, 274:36601-36608.
11. Raad H., Paclet M.H., Boussetta T., Kroviarski Y., Morel F., Quinn M.T., et al. Regulation of the phagocyte NADPH oxidase activity: phosphorylation of gp91phox/NOX2 by protein kinase C enhances its diaphorase activity and binding to Rac2, p67phox, and p47phox. FASEB J 2009, 23:1011-1022.
12. DeLeo F.R., Quinn M.T. Assembly of the phagocyte NADPH oxidase: molecular interaction of oxidase proteins. J Leuk Biol 1996, 60:677-691.
13. El-Benna J., Dang P.M., Gougerot-Pocidalo M.A., Marie J.C., Braut-Boucher F. p47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in diseases. Exp Mol Med 2009, 41:217-225.
14. Han C.H., Freeman J.L., Lee T., Motalebi S.A., Lambeth J.D. Regulation of the neutrophil respiratory burst oxidase. Identification of an activation domain in p67(phox). J Biol Chem 1998, 273:16663-16668.
15. Dang P.M., Morel F., Gougerot-Pocidalo M.A., Benna J.E. Phosphorylation of the NADPH oxidase component p67(PHOX) by ERK2 and P38MAPK: selectivity of phosphorylated sites and existence of an intramolecular regulatory domain in the tetratricopeptide-rich region. Biochemistry 2003, 42:4520-4526.
16. Bouin A.P., Grandvaux N., Vignais P.V., Fuchs A. p40(phox) is phosphorylated on threonine 154 and serine 315 during activation of the phagocyte NADPH oxidase. Implication of a protein kinase C-type kinase in the phosphorylation process. J Biol Chem 1998, 273:30097-30103.
17. El-Benna J., Dang P.M., Gougerot-Pocidalo M.A. Priming of the neutrophil NADPH oxidase activation: role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane. Semin Immunopathol 2008, 30:279-289.
18. Dang P.M., Stensballe A., Boussetta T., Raad H., Dewas C., Kroviarski Y., et al. A specific p47phox -serine phosphorylated by convergent MAPKs mediates neutrophil NADPH oxidase priming at inflammatory sites. J Clin Invest 2006, 116:2033-2043.
19. Bromberg Y., Pick E. Activation of NADPH-dependent superoxide production in a cell-free system by sodium dodecyl sulfate. J Biol Chem 1985, 260:13539-13545.
20. Dagher M.C., Pick E. Opening the black box: lessons from cell-free systems on the phagocyte NADPH-oxidase. Biochimie 2007, 89:1123-1132.
21. El-Benna J., Park J.W., Ruedi J.M., Babior B.M. Cell-free activation of the respiratory burst oxidase by protein kinase C. Blood Cells Mol Dis 1995, 21:201-206.
22. Erickson R.W., Langel-Peveri P., Traynor-Kaplan A.E., Heyworth P.G., Curnutte J.T. Activation of human neutrophil NADPH oxidase by phosphatidic acid or diacylglycerol in a cell-free system. Activity of diacylglycerol is dependent on its conversion to phosphatidic acid. J Biol Chem 1999, 274:22243-22250.
23. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87:245-313.
24. Geiszt M., Lekstrom K., Witta J., Leto T.L. Proteins homologous to p47phox and p67phox support superoxide production by NAD(P)H oxidase 1 in colon epithelial cells. J Biol Chem 2003, 278:20006-20012.
25. Bánfi B., Clark R.A., Steger K., Krause K.H. Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J Biol Chem 2003, 278:3510-3513.
26. Cheng G., Lambeth J.D. NOXO1, regulation of lipid binding, localization, and activation of Nox1 by the Phox Homology (PX) domain. J Biol Chem 2004, 279:4737-4742.
27. Takeya R., Ueno N., Kami K., Taura M., Kohjima M., Izaki T., et al. Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. J Biol Chem 2003, 278:25234-25246.
28. Cross A.R. Inhibitors of the leukocyte superoxide generating oxidase: mechanisms of action and methods for their elucidation. Free Radic Biol Med 1990, 8:71-93.
29. Lambeth J.D., Krause K.H., Clark R.A. NOX enzymes as novel targets for drug development. Semin Immunopathol 2008, 30:339-363.
30. Hancock J.T., Jones O.T. The inhibition by diphenyleneiodonium and its analogues of superoxide generation by macrophages. Biochem J 1987, 242:103-107.
31. Stuehr D.J., Fasehun O.A., Kwon N.S., Gross S.S., Gonzalez J.A., Levi R., et al. Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs. FASEB J 1991, 5:98-103.
32. Miesel R., Kurpisz M., Kroger H. Suppression of inflammatory arthritis by simultaneous inhibition of nitric oxide synthase and NADPH oxidase. Free Radic Biol Med 1996, 20:75-81.
33. Gustot T., Lemmers A., Moreno C., Nagy N., Quertinmont E., Nicaise C., et al. Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology 2006, 43:989-1000.
34. Masamune A., Watanabe T., Kikuta K., Satoh K., Shimosegawa T. NADPH oxidase plays a crucial role in the activation of pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2008, 294:G99-G108.
35. Stolk J., Hiltermann T.J., Dijkman J.H., Verhoeven A.J. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol 1994, 11:95-102.
36. Stefanska J, Pawliczak R. Apocynin: molecular aptitudes. Mediators Inflamm 2008;106507:10 [article ID 106507]. doi:10.1155/2008/106507.
37. Ximenes V.F., Kanegae M.P., Rissato S.R., Galhiane M.S. The oxidation of apocynin catalyzed by myeloperoxidase: proposal for NADPH oxidase inhibition. Arch Biochem Biophys 2007, 457:134-141.
38. Heumüller S., Wind S., Barbosa-Sicard E., Schmidt H.H., Busse R., Schröder K., et al. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 2008, 51:211-217.
39. 't Hart B.A., Simons J.M., Knaan-Shanzer S., Bakker N.P., Labadie R.P. Antiarthritic activity of the newly developed neutrophil oxidative burst antagonist apocynin. Free Radic Biol Med 1990, 9:127-131.
40. Hougee S., Hartog A., Sanders A., Graus Y.M., Hoijer M.A., Garssen J., et al. Oral administration of the NADPH-oxidase inhibitor apocynin partially restores diminished cartilage proteoglycan synthesis and reduces inflammation in mice. Eur J Pharmacol 2006, 531:264-269.
41. Zhou X., Bohlen H.G., Unthank J.L., Miller S.J. Abnormal nitric oxide production in aged rat mesenteric arteries is mediated by NAD(P)H oxidase-derived peroxide. Am J Physiol Heart Circ Physiol 2009, 297:H2227-H2233.
42. Le Cabec V., Maridonneau-Parini I. Complete and reversible inhibition of NADPH oxidase in human neutrophils by phenylarsine oxide at a step distal to membrane translocation of the enzyme subunits. J Biol Chem 1995, 270:2067-2073.
43. Diatchuk V., Lotan O., Koshkin V., Wikstroem P., Pick E. Inhibition of NADPH oxidase activation by 4-(2-aminoethyl)-benzenesulfonyl fluoride and related compounds. J Biol Chem 1997, 272:13292-13301.
44. Roussin A., Le Cabec V., Lonchampt M., De Nadaï J., Canet E., Maridonneau-Parini I. Neutrophil-associated inflammatory responses in rats are inhibited by phenylarsine oxide. Eur J Pharmacol 1997, 322:91-96.
45. Jaquet V., Scapozza L., Clark R.A., Krause K.H., Lambeth J.D. Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid Redox Signal 2009, 11:2535-2552.
46. Rotrosen D., Kleinberg M.E., Nunoi H., Leto T., Gallin J.I., Malech H.L. Evidence for a functional cytoplasmic domain of phagocyte oxidase cytochrome b558. J Biol Chem 1990, 265:8745-8750.
47. Nakanishi A., Imajoh-Ohmi S., Fujinawa T., Kikuchi H., Kanegasaki S. Direct evidence for interaction between COOH-terminal regions of cytochrome b558 subunits and cytosolic 47-kDa protein during activation of an O(2-)-generating system in neutrophils. J Biol Chem 1992, 267:19072-19074.
48. DeLeo F.R., Jutila M.A., Quinn M.T. Characterization of peptide diffusion into electropermeabilized neutrophils. J Immunol Methods 1996, 198:35-49.
49. Leusen J.H., de Boer M., Bolscher B.G., Hilarius P.M., Weening R.S., Ochs H.D., et al. A point mutation in gp91-phox of cytochrome b558 of the human NADPH oxidase leading to defective translocation of the cytosolic proteins p47-phox and p67-phox. J Clin Invest 1994, 93:2120-2126.
50. DeLeo F.R., Yu L., Burritt J.B., Loetterle L.R., Bond C.W., Jesaitis A.J., et al. Mapping sites of interaction of p47-phox and flavocytochrome b with random-sequence peptide phage display libraries. Proc Natl Acad Sci USA 1995, 92:7110-7114.
51. Yu L., Cross A.R., Zhen L., Dinauer M.C. Functional analysis of NADPH oxidase in granulocytic cells expressing a delta488-497 gp91(phox) deletion mutant. Blood 1999, 94:2497-2504.
52. Rey F.E., Cifuentes M.E., Kiarash A., Quinn M.T., Pagano P.J. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res 2001, 31:408-414.
53. Zhou M.S., Hernandez Schulman I., Pagano P.J., Jaimes E.A., Raij L. Reduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II, atherogenesis, and blood pressure. Hypertension 2006, 47:81-86.
54. Park L., Zhou P., Pitstick R., Capone C., Anrather J., Norris E.H., et al. Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci USA 2008, 105:1347-1352.
55. Park M.Y., Imajoh-Ohmi S., Nunoi H., Kanegasaki S. Synthetic peptides corresponding to various hydrophilic regions of the large subunit of cytochrome b558 inhibit superoxide generation in a cell-free system from neutrophils. Biochem Biophys Res Commun 1997, 234:531-536.
56. Tsuchiya T., Imajoh-Ohmi S., Nunoi H., Kanegasaki S. Uncompetitive inhibition of superoxide generation by a synthetic peptide corresponding to a predicted NADPH binding site in gp91-phox, a component of the phagocyte respiratory oxidase. Biochem Biophys Res Commun 1999, 257:124-128.
57. Kao Y.Y., Gianni D., Bohl B., Taylor R.M., Bokoch G.M. Identification of a conserved Rac-binding site on NADPH oxidases supports a direct GTPase regulatory mechanism. J Biol Chem 2008, 283:12736-12746.
58. Park M.Y., Imajoh-Ohmi S., Nunoi H., Kanegasaki S. Peptides corresponding to the region adjacent to His-94 in the small subunit of cytochrome b558 inhibit superoxide generation in a cell-free system from human neutrophils. Biochem Biophys Res Commun 1994, 204:924-929.
59. Dahan I., Issaeva I., Gorzalczany Y., Sigal N., Hirshberg M., Pick E. Mapping of functional domains in the p22(phox) subunit of flavocytochrome b(559) participating in the assembly of the NADPH oxidase complex by " peptide walking" J Biol Chem 2002, 277:8421-8432.
60. Nauseef W.M., McCormick S., Renee J., Leidal K.G., Clark R.A. Functional domain in an arginine-rich carboxyl-terminal region of p47phox. J Biol Chem 1993, 268:23646-23651.
61. DeLeo F.R., Nauseef W.M., Jesaitis A.J., Burritt J.B., Clark R.A., Quinn M.T. A domain of p47phox that interacts with human neutrophil flavocytochrome b558. J Biol Chem 1995, 270:26246-26251.
62. Labadia M.E., Zu Y.L., Huang C.K. A synthetic peptide containing a predominant protein kinase C site within p47phox inhibits the NADPH oxidase in intact neutrophils. J Leukoc Biol 1996, 59:116-122.
63. Morozov I., Lotan O., Joseph G., Gorzalczany Y., Pick E. Mapping of functional domains in p47(phox) involved in the activation of NADPH oxidase by " peptide walking" J Biol Chem 1998, 273:15435-15444.
64. Huang J., Kleinberg M.E. Activation of the phagocyte NADPH oxidase protein p47(phox). Phosphorylation controls SH3 domain-dependent binding to p22(phox). J Biol Chem 1999, 274:19731-19737.
65. Boussetta T., Raad H., Lettéron P., Gougerot-Pocidalo M.A., Marie J.C., Driss F., et al. Punicic acid a conjugated linolenic acid inhibits TNFalpha-induced neutrophil hyperactivation and protects from experimental colon inflammation in rats. PLoS One 2009, 4:e6458.
66. Kreck M.L., Uhlinger D.J., Tyagi S.R., Inge K.L., Lambeth J.D. Participation of the small molecular weight GTP-binding protein Rac1 in cell-free activation and assembly of the respiratory burst oxidase. Inhibition by a carboxyl-terminal Rac peptide. J Biol Chem 1994, 269:4161-4168.
67. Joseph G., Gorzalczany Y., Koshkin V., Pick E. Inhibition of NADPH oxidase activation by synthetic peptides mapping within the carboxyl-terminal domain of small GTP-binding proteins. Lack of amino acid sequence specificity and importance of polybasic motif. J Biol Chem 1994, 269:29024-29031.
68. Joseph G., Pick E. " Peptide walking" is a novel method for mapping functional domains in proteins. Its application to the Rac1-dependent activation of NADPH oxidase. J Biol Chem 1995, 270:29079-29082.
69. Diekmann D., Abo A., Johnston C., Segal A.W., Hall A. Interaction of Rac with p67phox and regulation of phagocytic NADPH oxidase activity. Science 1994, 265:531-533.
70. Shi J., Ross C.R., Leto T.L., Blecha F. PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox. Proc Natl Acad Sci USA 1996, 93:6014-6018.
71. Ikeda Y., Young L.H., Scalia R., Ross C.R., Lefer A.M. PR-39, a proline/arginine-rich antimicrobial peptide, exerts cardioprotective effects in myocardial ischemia-reperfusion. Cardiovasc Res 2001, 49:69-77.
72. Ni W., Zhan Y., He H., Maynard E., Balschi J.A., Oettgen P. Ets-1 is a critical transcriptional regulator of reactive oxygen species and p47(phox) gene expression in response to angiotensin II. Circ Res 2007, 101:985-994.
73. Qin L., Block M.L., Liu Y., Bienstock R.J., Pei Z., Zhang W., et al. Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress. FASEB J 2005, 19:550-557.
74. Jarver P., Langel U. The use of cell-penetrating peptides as a tool for gene regulation. Drug Discov Today 2004, 9:395-402.
75. Brooks H., Lebleu B., Vivès E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev 2005, 57:559-577.